Official Title
COVID CT, Beaumont Quantitative Lung Function Imaging to Characterize Patients With SARS-COV 2
Brief Summary

The goal of this study is to evaluate if CT (Computerized Tomography) can effectively and accurately predict disease progression in patients with SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2). You may be eligible if you have been diagnosed with SARS-CoV-2, are an inpatient at Beaumont Hospital-Royal Oak and meet eligibility criteria. After consent and determination of eligibility, enrolled patients will have a CT scanning session. After the CT scan, patients are followed for 30 days by reviewing their medical records and by phone after discharge from hospital.

Detailed Description

Beaumont Quantitative CT lung function imaging (BQLFI) uses mathematical modeling to

determine regional differences in ventilation (CT-V) and pulmonary blood mass (PBM) from a

pair of inspiration-expiration CT scans or time-resolved four-dimensional (4D) CT scans. CT-V

and PBM images provide surrogates for pulmonary ventilation and perfusion, respectively, in

the form of detailed functional maps. CT-V and PBM therefore allow us to distinguish healthy

from abnormal lung. Moreover, the technique generalizes to recover lung compliance imaging

(LCI) when the CT is acquired at different pressure settings, in order to characterize lung

stiffness. PBM and CT-V can detect parenchymal lung function changes at a voxel level and can

be used to 1) assess disease progression in SARS-CoV-2, 2) detect treatment effects, and 3)

identify early changes in high-risk patients prior to their development of disease. BQLFI

affords the opportunity to provide imaging biomarkers that enable the early diagnosis of lung

injury, which in turn cause impairment in gas exchange at the level of alveolar capillary

interface. Currently, there are no available imaging biomarkers to predict patients at risk

of progression or identify those at risk of developing severe disease with SARS-CoV-2. Our

proposed study will validate a novel methodology, based on state-of-the-art CT-V and PBM

imaging that can accurately measure regional ventilation and perfusion, as a means for

improving surveillance, diagnosis, and prognostication of patients with SARS-CoV-2. This is a

prospective, pilot study of 25 adult patients with SARS-CoV-2, who have mild to moderate

disease, defined as positive PCR screen and not requiring invasive mechanical ventilator

support or noninvasive ventilation or high flow nasal cannula. Participants will provide

informed consent and eligibility will be confirmed. Demographics and medical history will be

obtained. Participants will undergo one inspiration-expiration CT. Outcomes and adverse

events will be assessed over 30 day using chart review or phone interview.

Severe Acute Respiratory Syndrome

Device: CT-V
CT-V is an image processing-based modality that recovers changes in local tissue volumes, induced by respiratory motion, from an inspiration-expiration CT (IE-CT) scan or a standard non-contrast 4D CT scan
Patients with SARS-COV 2

Eligibility Criteria

Inclusion criteria: 1. Adults >18 years of age 2. Informed consent 3. A confirmed diagnosis of SARS-CoV-2 with mild to moderate disease defined as oxygen > 90% on room air on or supplemental oxygen not more than 6L 4. Concomitant medications for the treatment are allowed

Exclusion criteria: 1. Patients

Eligibility Gender
Eligibility Age
Minimum: 18 Years
United States

Beaumont Health
Royal Oak, Michigan, 48073


Investigator: Joanne Gondert, RN, BSN
Contact: 248-898-0343


Joanne Gondert, RN, BSN

Girish B Nair, MD
Principal Investigator
William Beaumont Hospitals

William Beaumont Hospitals
NCT Number
Quantitative CT Lung Function Imaging
Pulmonary Blood Mass
MeSH Terms
Severe Acute Respiratory Syndrome
Coronavirus Infections